September 14, 2017 / 9:39 AM / a year ago

CORRECTED-Pfizer, Astellas prostate cancer drug clears late-stage trial

(Corrects headline and first paragraph to “prostate” from “prostrate”)

Sept 14 (Reuters) - Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

The oral drug, Xtandi, in combination with an anti-hormone therapy was more successful than an anti-hormone therapy alone in improving overall survival in men with non-metastatic castration-resistant prostate cancer.

The drug is already approved to treat metastatic castration-resistant prostate cancer. (Reporting by Tamara Mathias in Bengaluru; Editing by Savio D’Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below